Posted on Frankfurt am Main, Mörfelden-Walldorf

AMICI takes the next step – leading the premium medical cannabis market with new THC levels.

After launching a new premium medical cannabis brand under the name “AMICI” in Mid-November, Cansativa Group, Germany’s leading cannabis platform, now closes the year of 2022 with a new high THC product, which sets itself at the top of the medical cannabis market.

The previously launched product line consists of the two types “Strawberry Banana” and “Cherry Pie” and features high microbiological purity beside particular product details, which have been tested by experts and patients in the last weeks. Other high-quality cultivars from selected suppliers can be offered under the AMICI brand in the future as Cansativa sees AMICI as an open-source brand. The cultivars come from indoor cultivation facilities with many years of experience and strictly GMP-controlled, which reflects in a particularly safe product quality.

The new premium product will be distributed directly to pharmacies and selected wholesalers in the coming days. Patients can obtain further information, such as THC levels and other specific characteristics, from their trusted pharmacy or the Cansativa partner program pharmacies. 

More information about the new AMICI variety from 15.12.2022 at www.amici-cannabis.de.

Order directly (for professionals only): www.cansativa.de

“This new product is the icing on that final sprint of 2022 after the successful launch of the AMICI brand and the great feedback from our customers over the past few weeks. We are incredibly proud of the entire team who provides access to new medical cannabis products on a daily basis. With the help of our strong suppliers and our (partner) pharmacy network, we are able to pass on the high quality to the patients,” says CEO and co-founder Benedikt Sons.

About Cansativa Group

Cansativa Group is the market leader in the medical cannabis market and sees itself as a driving force of the cannabis industry in Germany. Since the award by the Federal Institute for Drugs and Medical Devices (BfArM) in August 2020, they are the only company commissioned for the distribution of medical cannabis from German cultivation. In the upcoming cannabis legalization, Cansativa Group sees itself as a pioneer in the democratization of the cannabis market.


Press contact:
Ioana Freise
pr@cansativa.de

 


Press release